At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 526 enrolled
Drug / intervention
0.15% azelastine hydrochloride 1644 mcg daily +2 moredrug
Likely dose
0.15% azelastine hydrochloride 1644 mcg dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 and MP03-33 Compared to Placebo in Patients With Seasonal Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating 0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, and 1 other intervention for Seasonal Allergic Rhinitis. Completed, enrolled 526 participants across 29 sites.
Detailed Summary
The purpose of this study was to determine if two allergy medications are more effective than placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
Primary CompletionOct 2007
Study CompletionNov 2007
First PostedJul 2008
TodayJul 2026
First PostedJul 22, 2008
Enrollment StartAug 1, 2007
Primary CompletionOct 1, 2007
Study CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.9 years ago
Interventions
0.15% azelastine hydrochloride 1644 mcg dailydrug
0.15% azelastine hydrochloride 1644 mcg daily
0.1% azelastine hydrochloride 1096 mcg dailydrug
0.1% azelastine hydrochloride 1096 mcg daily
Placebodrug
0 mcg Placebo daily